拜玛林制药 BMRN 深 沪
等待开盘 03-27 09:30:00 美东时间
55.55
-0.040
-0.07%
华盛通- 最 高61.97
- 今 开55.36
- 成交量 92.59万股
- 最 低 53.355
- 昨 收 55.59
- 总市值 1027.68万
- 52周最高 66.275
- 市盈率 静 --
- 换手率 500.49%
- 52周最低 50.76
- 委 比 64.52%
- 总股本 0.00亿
- 历史最高 151.75
- 量 比 0.58
- 振 幅 15.50%
- 历史最低 1.10
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory filings and potential commercial launches.
03-11 02:49
BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients
The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older.
03-02 19:10
Earnings Scheduled For February 23, 2026
Companies Reporting Before The Bell • Domino's Pizza (NASDAQ:DPZ) is likely to ...
02-23 19:11
Reported Earlier: BioMarin Launches $2B Term Loan B Financing To Fund Pending Amicus Therapeutics Acquisition
BioMarin also announced that, in connection with the pending acquisition (the "Acquisition") of Amicus Therapeutics, Inc. ("Amicus"), it launched the syndication of a new $2 billion senior secured term loan "B" facility
01-26 21:49
BioMarin Pharmaceutical Plans To Offer $850M Senior Notes Due 2034 Offering
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured notes due 2034 (the "Notes").
01-26 20:47
Nasdaq Surges Over 1%; Lamb Weston Shares Decline Following Q2 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
2025-12-20 01:16
BioMarin Boosts Rare Disease Portfolio With Amicus Buyout, Stocks Rally
BioMarin acquires Amicus for $4.8B, expanding its rare disease portfolio with Fabry and Pompe therapies, in a deal expected to close Q2 2026.
2025-12-20 00:07
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst
CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 clinical milestones.
2025-12-19 23:36
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
Inozyme Pharma has postponed its 2025 Annual Meeting due to the pending acquisition by BioMarin Pharmaceutical Inc. If the acquisition is completed, the Annual Meeting will not occur. If not, the Board will decide on further steps to reschedule the meeting.
2025-06-20 21:00
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
Biomarin Pharmaceutical (NASDAQ:BMRN) has outperformed the market over the past...
2024-09-23 22:00
